Isotopia Molecular Imaging Ltd. is thrilled to announce that Isoprotrace®, has received marketing authorization in the Netherlands (RVG 130527)

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Isoprotrace-RVG130527

More Like This

PR Newswire associated0

Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals

Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

PR Newswire associated0

Positrigo Secures CE Mark in Europe for its Pioneering Dedicated Brain PET System

GlobeNewswire associated0

KOELIS announces the first interim results of the VIOLETTE trial which evaluates the use of OBT-Fusion® technology in focal ablation of the prostate by microwave needles

Blue Earth Diagnostics Ltd Collaborates with Sinotau Pharmaceutical Group to Bring Prostate Cancer PET Diagnostic Imaging Agent, Flotufolastat (18F) Injection, to China

PR Newswire associated0

Perceptive Imaging Improves Oncology Trial Outcomes through Enhanced Services

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors

PR Newswire associated0

First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591